The Efficacy of Levocarnitine Combined with Trimetazidine in the Treatment of Dilated Cardio-myopathy and its Impact on Patients'Cardiac Function
[Objective]To investigate the clinical efficacy of levocarnitine combined with trimetazidine in the treatment of dilated cardiomyopathy(DCM)and its impact on patients'cardiac function.[Methods]A total of 102 DCM patients admitted to our hospital from January 2022 to February 2023 were selected and randomly divided into a control group(treated with trimetazidine in addition to conventional medication)and an observa-tion group(treated with levocarnitine in addition to the control group)using a random number table method,with 51 patients in each group.Two groups of therapeutic effects were compared,including pre-and post-treat-ment cardiac function indicators such as cardiac index(CI),left ventricular ejection fraction(LVEF),left ven-tricular end diastolic diameter(LVEDD),laboratory indicators such as periostin protein,transforming growth factor-β1(TGF-β1),soluble growth stimulating gene 2 protein(sST2),cardiac troponin T(cTnT),creatine kinase isoenzyme(CK-MB),and myoglobin(Mb).[Results]The total effective rate of the observation group was significantly higher than that of the control group,and the difference was statistically significant(P＜0.05).After treatment,the CI and LVEF of both groups were higher than before treatment,and the observa-tion group was higher than the control group;The LVEDD of both groups was lower than before treatment,and the observation group was lower than the control group,with a statistically significant difference(P＜0.05).After treatment,cTnT,CK-MB,Mb,Periostin protein,TGF-β1,and sST2 in both groups were lower than before treatment,and the observation group was lower than the control group,with statistical signifi-cance(P＜0.05).[Conclusion]The combination of levocarnitine and trimetazidine is effective in treating DCM patients,improving their cardiac function and inhibiting ventricular remodeling.
万方数据
维普
